19 results on '"Fridhammar, Adam"'
Search Results
2. Examining the Impact of Structural Uncertainty Across 10 Type 2 Diabetes Models: Results From the 2022 Mount Hood Challenge
3. MRI-only radiotherapy from an economic perspective: Can new techniques in prostate cancer treatment be cost saving?
4. The implementation of a noninvasive lymph node staging (NILS) preoperative prediction model is cost effective in primary breast cancer
5. Cost-Effectiveness of Once-Weekly Semaglutide 1 mg versus Canagliflozin 300 mg in Patients with Type 2 Diabetes Mellitus in a Canadian Setting
6. Long-Term Cost Effectiveness of Oral Semaglutide Versus Empagliflozin and Sitagliptin for the Treatment of Type 2 Diabetes in the Swedish Setting
7. The Key Role of Patient Involvement in the Development of Core Outcome Sets in Prostate Cancer
8. Recombinant FVIII replacement products for haemophilia A: An updated valuation by indirect comparison measuring area under the curve.
9. The Value of a New Diagnostic Test for Prostate Cancer: A Cost-Utility Analysis in Early Stage of Development
10. Intraductal papillary mucinous neoplasms of the pancreas – a cost-effectiveness analysis of management strategies for the branch-duct subtype
11. Correction to: Cost-Effectiveness of Once-Weekly Semaglutide 1 mg versus Canaglifozin 300 mg in Patients with Type 2 Diabetes Mellitus in a Canadian Setting
12. Survivorship Data in Prostate Cancer: Where Are We and Where Do We Need To Be?
13. The Value of a New Diagnostic Test for Prostate Cancer: A Cost-Utility Analysis in Early Stage of Development
14. The Key Role of Patient Involvement in the Development of Core Outcome Sets in Prostate Cancer
15. 38 - Cost Effectiveness of Oral Semaglutide 14 mg Vs Empagliflozin 25 mg in Canada
16. 1163-P: Cost Effectiveness of Oral Semaglutide 14mg vs. Empagliflozin 25mg in Canada
17. Comparing the Cohort and Micro-Simulation Modeling Approaches in Cost-Effectiveness Modeling of Type 2 Diabetes Mellitus: A Case Study of the IHE Diabetes Cohort Model and the Economics and Health Outcomes Model of T2DM
18. Cost-effectiveness of once-weekly semaglutide versus dulaglutide and lixisenatide in patients with type 2 diabetes with inadequate glycemic control in Sweden
19. Cost-effectiveness of liraglutide versus lixisenatide as add-on therapies to basal insulin in type 2 diabetes
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.